ULGX Key Stats
- UROLOGIX INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Con... May 23
- UROLOGIX INC Files SEC form 10-Q, Quarterly Report May 14
- UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition, ... May 2
- Urologix's CEO Discusses F3Q 2013 Results - Earnings Call Transcript Seeking Alpha May 1
- Urologix, Inc. Earnings Call scheduled for 5:00 pm ET today May 1
- Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Gui... May 1
- Urologix, Inc. (ULGX) Tops Q3 Views Street Insider May 1
- Q3 2013 Urologix, Inc. Earnings Release - After Market Close May 1
- Urologix to Host Its Fiscal Year 2013 Third Quarter Conference Call Business Wire Apr 25
- UROLOGIX INC Files SEC form 8-K, Other Events Apr 17
ULGX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Urologix is down 49.00% over the last year vs S&P 500 Total Return up 28.33%, Medtronic up 42.68%, and St Jude Medical up 19.17%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ULGX
Pro Report PDF for ULGX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ULGX Pro Report PDF
Pro Strategies Featuring ULGX
Did Urologix make it into our Pro Portfolio Strategies?